Nur77 Inhibit β-catenin Expression to Mediate Hepatoblastoma Progression and Therapeutic Effect of Cisplatin

Author:

Zhou Jianfeng1,Liu Xingyu2,Yin Hanjun3,Zhou Yong1,Xu Zhongya1,Zhou Kai2,Li Tao1,Fang Yongjun1,Shen Qiyang1

Affiliation:

1. Children's Hospital of Nanjing Medical University

2. First Affiliated Hospital of Bengbu Medical College

3. Nanjing Drum Tower Hospital Group Suqian Hospital

Abstract

Abstract Hepatoblastoma (HB) is the most common malignant tumor in children under 5 years old, but its pathogenesis remains unclear. Nur77 has been reported to be an important regulator for cancer progression in various cancer types. This study found that Nur77 was downregulated in HB tumors, compared with paracancer tissue. Knockout or overexpression of Nur77 in HB tumor cell line HepG2 and HuH6 could significantly enhance or inhibit the proliferation, migration and invasion of tumor cells both in vitro and in vivo. Further studies illustrated that Nur77 regulated the proliferation of tumor cells by affecting the expression of β-catenin. Nur77 agonist Cns-A effectively enhanced the therapeutic effect of cisplatin on HB tumors both in vitro and in vivo. This study proved that Nur77 could act as a tumor suppressor gene in HB tumors, providing a new direction for improving the clinical responses of HB.

Publisher

Research Square Platform LLC

Reference35 articles.

1. Incidence trends and survival prediction of hepatitis in children: a population-based study;Feng J;Cancer Commun (Lond),2019

2. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration;Meyers RL;Lancet Oncol,2017

3. Management of hepatitis: an update;Kremer N;Curr Opin Pediatr,2014

4. Predictors of survival and incidence of hepatitis in the pediatric population;Allan BJ;HP B (Oxford),2013

5. Survival trends in children with hepatitis;Horton JD;Pediatr Surg Int,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3